COMMUNIQUÉS West-GlobeNewswire

Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004
27/01/2026
CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 million people in the U.S. alone In prior studies, CBT-004 demonstrated an ability to modify [...]
Bicycle Health Appoints Rick Dean as Chief Executive Officer to Lead Next Phase of Growth
27/01/2026
Former OncoHealth CEO joins Bicycle Health to continue the company’s momentum ATLANTA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bicycle Health , the nation’s leading technology-enabled virtual medical group delivering scalable [...]
Canix Acquires Major Competitor Trym To Create Industry-Leading ERP Management For Cannabis Industry
27/01/2026
Acquisition strengthens cultivation intelligence as Canix positions itself as the premier ERP platform for cannabis operators amid industry consolidation and federal rescheduling SAN FRANCISCO, Jan. 27, 2026 (GLOBE [...]
Science 37 Appoints Kelly Johnston McKee as VP of Strategy & Transformation
27/01/2026
MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Science 37 , the leader in expanding patient access to clinical trials, today announced the appointment of Kelly Johnston McKee as Vice President, Strategy & [...]
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
27/01/2026
“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, [...]
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
27/01/2026
PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a [...]
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
27/01/2026
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial [...]
First Steroid Cycle for Bodybuilders – CrazyBulk | Steroids for Beginners Bulking and Cutting: Safest Steroids for Bodybuilding
27/01/2026
New York City, NY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- The decision of a beginning user on his or her first steroid cycle is a significant milestone for bodybuilders and athletes. Since a high number of beginners who take [...]
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
27/01/2026
Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer Prevention MELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc [...]
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
27/01/2026
Lisata regains full development rights to certepetide in the Greater China Region BASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical- [...]
PreatLoc™ by Preat® is Now Available
27/01/2026
Preat Corporation introduces PreatLoc™, an overdenture attachment system providing compatibility, reliability and precise performance SANTA MARIA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- A leader in dental implant [...]
Halo Pharma to become a stand-alone Drug Product Contract Development and Manufacturing Organization (CDMO)
27/01/2026
SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) The transaction is subject to customary closing conditions and regulatory [...]
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
27/01/2026
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: [...]
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
27/01/2026
CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced [...]
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
27/01/2026
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in lesion growth (p- [...]
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
27/01/2026
Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD program HD is a rare, progressive genetic disorder often described as a [...]
Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned
27/01/2026
Tablo becomes first dialysis system to clear FDA’s most rigorous cybersecurity standards SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a [...]
Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma
27/01/2026
BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and Drug Administration has [...]
Acentra Health Appoints Balajee Sethuraman as Executive Vice President and Chief Business Services Officer
27/01/2026
Seasoned healthcare and technology leader to oversee business services and delivery operations MCLEAN, Va., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health solutions company dedicated to [...]

Pages